Every Form 4 that Vistagen Therapeutics Inc (VTGN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow VTGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VTGN filings page.
Williamson Douglas J reported acquisition or exercise transactions in this Form 4 filing.
Vistagen Therapeutics director Douglas J. Williamson received a grant of 40,826 stock options on July 29, 2026, each exercisable at $0.2433 per share for common stock. The options, granted in connection with his appointment to the Board under the company’s 2019 equity plan, vest in three equal annual installments beginning one year after grant and expire on July 29, 2036. Following this award, he holds 40,826 options, and no sales or purchases of common shares were reported.
Vistagen Therapeutics Chief Legal Officer Reid G. Adler increased his holdings through the company’s employee stock purchase plan. Adler acquired 36,818 shares of common stock on June 30, 2026 at an average price of $0.1921 per share, pursuant to Vistagen’s 2019 Employee Stock Purchase Plan.
This compensation-related transaction is classified as a grant or award acquisition and was exempt under Rule 16b-3. Adler purchased the maximum amount permitted under the plan and now directly owns 60,868 shares of Vistagen common stock.
Tressler Nick B. reported acquisition or exercise transactions in this Form 4 filing.
Vistagen Therapeutics, Inc. Chief Financial Officer Nick B. Tressler received 11,712 shares of common stock on June 30, 2026 through the company’s 2019 Employee Stock Purchase Plan at $0.1921 per share. Following this compensation-related grant, he directly holds 11,712 shares.
Vistagen Therapeutics, Inc. President and CEO Shawn Singh acquired shares of the company through an employee stock purchase program. He received 36,818 shares of common stock at a purchase price of $0.1921 per share under Vistagen's 2019 Employee Stock Purchase Plan, as amended. This plan-related acquisition is classified as a grant or award and is exempt under Rule 16b-3.
Following this acquisition, Singh directly holds 54,846 shares of Vistagen common stock. The filing also reports an additional 20,875 shares of common stock held indirectly by The 1997 Singh Family Trust U/R/D 05/29/1997, reflecting family trust ownership separate from his direct holdings.
Vistagen Therapeutics reported a Form 4 showing its Chief Medical Officer, Angel S. Angelov, received a grant of stock options for 150,000 shares of common stock at an exercise price of $0.5955 per share. The options expire on May 18, 2036 and were granted in connection with his appointment as Chief Medical Officer, with 25% vesting on May 18, 2027 and the remaining options vesting monthly over the following three years.
Vistagen Therapeutics, Inc. reported that Chief Financial Officer Nick B. Tressler received a grant of 75,000 Incentive Stock Options to purchase common stock at an exercise price of $0.5358 per share, expiring on April 7, 2036.
According to the grant terms, 25% of these options will vest on the six-month anniversary of April 7, 2026, with additional 25% installments vesting every six months until the options are fully vested on the two-year anniversary of the grant date. This is a compensation award, not an open-market purchase or sale.
Vistagen Therapeutics reported that President and CEO Shawn Singh received grants of incentive and non-qualified stock options covering a total of 75,000 shares of common stock at an exercise price of $0.5358 per share. According to the grant terms, 25% of the options will vest on the six-month anniversary of April 7, 2026, with additional 25% installments vesting every six months until they are fully vested on the two-year anniversary of the grant date. The options expire on April 7, 2036.
Vistagen Therapeutics, Inc. granted Chief Operating Officer Joshua S. Prince two stock option awards on April 7, 2026 under its Amended and Restated 2019 Omnibus Equity Incentive Plan. He received an Incentive Stock Option for 18,752 shares and a Non-Qualified Stock Option for 56,248 shares of common stock.
Both option grants have an exercise price of $0.5358 per share and expire on April 7, 2036. According to the vesting schedule, 25% of the options will vest on the six-month anniversary of the April 7, 2026 grant date, with additional 25% installments vesting every six months until fully vested on the two-year anniversary of the grant date. These awards represent compensation-related grants rather than open-market purchases or sales.
Vistagen Therapeutics, Inc. reported that Chief Corp Development Officer Elissa S. Cote received a grant of stock options covering 75,000 shares of common stock. The options have an exercise price of $0.5358 per share and expire on April 7, 2036.
According to the grant terms, 25% of the options will vest on the six-month anniversary of April 7, 2026, with additional 25% installments vesting every six months until they are fully vested on the two-year anniversary of the grant date. This is a compensation-related award rather than an open-market purchase.
Vistagen Therapeutics, Inc. disclosed that Chief Legal Officer Reid G. Adler received two stock option grants on April 7, 2026 under the company’s Amended and Restated 2019 Omnibus Equity Incentive Plan. He was granted an Incentive Stock Option for 18,753 shares and a Non-Qualified Stock Option for 56,247 shares of common stock, each with an exercise price of $0.5358 per share and expiring on April 7, 2036. According to the vesting terms, 25% of each option vests on the six-month anniversary of the April 7, 2026 grant date, with additional 25% installments every six months until fully vested on the two-year anniversary of the grant date.
Vistagen Therapeutics (VTGN) reported a routine insider transaction. Director Paul R. Edick acquired 35,200 stock options on 10/27/2025 at an exercise price of $3.9 per share. The options were granted in connection with his appointment to the Board and were issued under the company’s Amended and Restated 2019 Omnibus Equity Incentive Plan.
The options vest in three equal annual installments beginning on the first anniversary of the grant date and expire on 10/27/2035. Following the transaction, 35,200 derivative securities were beneficially owned directly.